Huprine X and huperzine a improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD)

Neurodegenerative Diseases

Volumn 11, Issue 3, 2013, Pages 129-140

  Ratia, M ^a   Gimenez Llort L ^b   Camps, P ^c   Munoz Torrero D ^c   Perez B ^a   Clos, M V ^a   Badia, A ^a,b  

^a Departament de Farmacologia   (Spain)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Secretases (TACE ADAM17); 3xTg AD mice; Acetylcholinesterase inhibitors; Cognitive improvement; Glycogen synthase kinase 3 ; Huperzine A; Huprine X; Learning and memory; Mitogen activated protein kinase; Protein kinase C

Indexed keywords

ADAM10 ENDOPEPTIDASE; CHOLINESTERASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HUPERZINE A; HUPRINE X; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; ADAM17 PROTEIN; PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DISSECTION; DRUG EFFECT; DRUG EFFICACY; EMOTIONALITY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; HOMOZYGOSITY; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; MOUSE; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE MEMORY; SIGNAL TRANSDUCTION; SPATIAL LEARNING; SPATIAL MEMORY; TRANSGENIC MOUSE; TREATMENT DURATION; CHOLINERGIC TRANSMISSION; MORRIS WATER MAZE TEST; WESTERN BLOTTING;

ALKALOIDS; ALZHEIMER DISEASE; AMINOQUINOLINES; ANIMALS; BRAIN CHEMISTRY; CEREBRAL CORTEX; COGNITION DISORDERS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; SESQUITERPENES;

EID: 84873087083     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000336427     Document Type: Article

References (50)

1. Bartus RT: On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529
2. Francis PT, Nordberg A, Arnold SE: A preclinical view of cholinesterase inhibitors in neuroprotection : Do they provide more than symptomatic benefits in Alzheimer's diseasëTrends Pharmacol Sci 2005; 26: 104-111
3. Nordberg A: Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20(2 SUPPL1):S12-S18
4. Racchi M, Mazzucchelli M, Sironi M, Govoni S: Role protein kinase C in the regulated secretion of the amyloid precursor protein. Mol Psychiatry 2003; 8: 209-216
5. Banyopadhyay S, Glodstein LE, Lahiri DK, Rogers JT: Role of the APP non-Amyloidogenic signalling pathway and targeting -secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 2007; 14: 2848-2864
6. Bar-Am O, Yogev-Falach M, Ami T, Sagi Y, Youdim BH: Regulation of protein kinase C by the anti-Parkinson drug, MAO-B, rasagiline and its derivatives, in vivo J Neurochem 2004; 89: 1119-1125
7. Yogev-Falach M, Amir T, Bar-Am O, Weinstock M, Youdim MBH: The involvement of mitogen-Activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002; 16: 1674-1676
8. Zhang HY, Yan H, Tang XC: Non-cholinergic effects of huperzine A: Beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 2008; 28: 173-183
9. Fu H, Dou J, Li W, Cui W, Mak S, Hu Qu, Luo J, Lam CS, Pang Y, Youdim MB, Han Y: Promising multifunctional anti-Alzheimer's dimer bis(7)-cognitin acting as an activator of protein kinase C regulates activities of -secretase and BACE-1 concurrently. Eur J Pharmacol 2009; 623: 14-21
10. Zimmermann M, Gardoni F, Marcello E, Colciaghi F, Borrono B, Padovani A, Cattabeni F, Di Luca M: Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004; 90: 1489-1499
11. Wang R, Yan H, Tang XC: Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1-26
12. Camps P, El Achab R, Morral J, Muñoz-Torrero D, Badia A, Baños JE, Vivas NM, Barril X, Orozco M, Luque FJ: New tacrine-huperzine A hybrids (huprines): Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 2000: 43: 4657-4666
13. Camps P, Cusack B, Mallender WD, El Achab R, Morral J, Muñoz-Torrero D, Rosenberry TL: Huprine X is a novel high-Affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000; 57: 409-417
14. Román S, Vivas NM, Badia A, Clos MV: Interaction of a new potent anticholinesterasic compound (+/-) huprine X with muscarinic receptors in rat brain. Neurosci Lett 2002; 325: 103-106
15. Román S, Badia A, Camps P, Clos MV: Potentiation effects of (+/-) huprine X, a new anticholinesterasic inhibitor, on nicotinic receptors in rat cortical synaptosomes. Neuropharmacology 2004; 46: 95-102
16. Pera M, Roman S, Ratia M, Camps P, Muñoz-Torrero D, Colombo L, Manzoni C, Salmona M, Badia A, Clos MV: Acetylcholinesterase triggers the aggregation of PrP 106-126. Biochem Biophys Res Commun 2006; 346: 89-94
17. Ratia M, Giménez-Llort L, Camps P, Muñoz-Torrero D, Clos MV, Badia A: Behavioural effects and regulation of PKC and MAPK by huprine X in middle aged mice. Pharmacol Biochem Behav 2010; 95: 485-493
18. Oddo S, Cacamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A and synaptic dysfunction. Neuron 2003; 39: 409-421
19. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST: Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signalling. J Biol Chem 2008; 283: 9359-9368
20. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, Uchida T, Imahori K: Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 1993; 325: 167-172
21. Alvarez G, Muñoz-Montano JR, Satrustegui J, Avila J, Bogonea E, Díaz-Nido J: Lithium protects cultured neurons against beta-Amyloid induced neurodegeneration. FEBS Lett 1999; 453: 260-264
22. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM: Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA 2002; 99: 6334-6339
23. Zhang HY, Yan H, Tang XC: Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C- in intracerebroventricular -Amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004; 360: 21-24
24. Giménez-Llort L, Fernández-Teruel A, Escorihuela RM, Fredholm BB, Tobeña A, Pekny M, Johansson B: Mice lacking the adenosine A 1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002; 16: 547-550
25. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, LaFerla FM, Fernández-Teruel A: A modeling behavioural and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. Neurosci Biobehav Rev 2007; 31: 125-147
26. Lang UE, Lang F, Richter K, Vallon V, Lipp H-P, Schnermann J, Wolfer DP: Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Res 2003; 145: 179-188
27. Allinson TM, Parkin ET, Turner AJ, Hooper NM: ADAMS family members as amyloid precursor protein-Alpha-secretases. J Neurosci Res 2003; 74: 342-352
28. Hernández F, Gómez de Barreda E, Fuster-Mantanzo A, Lucas JJ, Avila J: GSK3: A possible link between beta amyloid and tau protein. Exp Neurol 2010; 223: 322-325
29. Schildein S, Huston J.P, Schwarting RK: Injections of tacrine and scopolamine into the nucleus acumbens: Opposing effects of immediate vs delayed posttrial treatment on memory of an open field. Neurobiol Learn Mem 2000; 72: 21-30
30. Tang XC, Han YF: Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev 1999; 5: 281-300
31. Carriero DL, Outslay G, Mayorga AJ, Aberman J, Gianutsos G, Salamone JD: Motor dysfunction produced by tacrine administration in rats. Pharmacol Biochem Behav 1997; 58: 851-858
32. Adem A, Jossan SS, Oreland J: Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 1989; 107: 313-317
33. Alkon DL, Sun MK, Nelson TJ: PKC signaling deficits: A mechanistic hypothesis of the origins of Alzheimer's disease. Trends Pharmacol Sci 2007; 28: 51-60
34. Buxbaum JD, Koo EH, Greengard P: Protein phosphorylation inhibits production of Alzheimer amyloid /A4 peptide. Proc Natl Acad Sci USA 1993; 90: 9195-9198
35. Hung AJ, Haass C, Nistch RM., Qiu WQ, Citron M, Wurtman RJ, Growdon JH, Selkoe DJ: Activation of protein kinase C inhibits cellular production of the amyloid protein. J Biol Chem 1993; 268: 22959-22962
36. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM: Protein-kinase C-Dependent alpha-secretase competes with betasecretase for cleavage of amyloid-beta precursor protein in trans-Golgi network. J Biol Chem 2000; 275: 2568-2575
37. Hongpaisan J, Sun M-K, Alkon DL: PKC activation prevents synaptic loss, A elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 2011; 31: 630-643
38. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerreti DP, Black RA: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273: 27765-27767
39. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F: Constitutive and regulated alphasecretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999; 96: 3922-3927
40. Nunan J, Small DH: Regulation of APP cleavage by alpha-, beta- And gamma-secretases. FEBS Lett 2000; 483: 6-10
41. Hedberg MM, Clos MV, Ratia M, González D, Unger Lithner Ch, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A: Effect of huprine X on -Amyloid, synaptophysin and 7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APP Swe transgenic mice. Neurodegener Dis 2010; 7: 379-388
42. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-307
43. Haring R, Fischer A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, Heldman E: Mitogen-Activated protein kinase-Dependent and protein kinase C-Dependent pathways link the m1 muscarinic receptor to beta-Amyloid precursor secretion. J Neurochem 1998; 71: 2094-2103
44. Desdouits-Magnen J, Desdouits F, Takeda S, Sy LJ, Saltiel AR, Buxbaum J, Czernik AJ, Nairn AC, Greengard PJ: Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-Activated protein kinase cascade. J Neurochem 1998; 70: 524-530
45. Mills J, Charest DL, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB: Regulation of amyloid precursor protein catabolism involves the mitogen-Activated protein kinase signal transduction pathway. J Neurosci 1997; 17: 9415-9422
46. Mills J, Reiner PB: Regulation of amyloid precursor protein cleavage. J Neurochem 1999; 72: 443-460
47. Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3 beta in cellular signalling. Prog Neurobiol 2001; 65: 391-426
48. Morishima-Kawashima M, Hasegawa M, Takio K, Susuki M, Yoshida H, Titani K, Hihara Y: Proline-Directed and non-prolinedirected phosphorylation of PHF tau. J Biol Chem 1995; 270: 823-829
49. Towsend M, Mehta T, Selkoe DJ: Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007; 282: 33305-33312
50. Martínez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Parsons CG, Gupta S, Banerjee P, LaFerla FM: Memantine improves cognition and reduces Alzheimer'slike neuropathology in transgenic mice. Am J Pathol 2010; 176: 870-880